ARE

Business Context and Reporting Period

Alexandria Real Estate Equities, Inc. (ARE) is a life science REIT focused on developing, operating, and redeveloping collaborative "Megacampus" ecosystems in major innovation clusters. This summary covers the quarterly period ended March 31, 2026.

• Portfolio: 35.8 million rentable square feet (RSF) of operating properties and 3.4 million RSF under construction.
• Occupancy: Operating occupancy declined to 87.7% from 90.9% in the prior quarter, driven by key lease expirations and tenant wind-downs.
• Market Position: Maintains investment-grade credit ratings (BBB+/Baa1) and a weighted-average debt maturity of 10.0 years.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 11.5% year-over-year to $671.0 million, primarily due to real estate dispositions completed since January 2025 and a decrease in same-property occupancy.
• Net Income Surge: GAAP net income increased significantly to $398.4 million (from $38.7 million) driven by a $366.4 million gain on early extinguishment of debt resulting from tender offers to repurchase $1.33 billion of senior notes at a discount.
• FFO Decline: FFO as adjusted decreased to $1.73 per share (from $2.30) due to lower same-property net operating income (NOI) and higher interest expense, offsetting the non-recurring debt gain.
• Impairments: Real estate impairment charges were $5.5 million, a significant decrease from $32.2 million in Q1 2025. The current quarter's charge relates to the Canada portfolio sale agreement amendment.
• Investment Loss: Investment loss narrowed to $4.6 million (from $50.0 million) due to reduced unrealized losses on non-real estate investments.

Guidance, Outlook, and Risks

2026 Guidance Updates (Midpoint)

• FFO As Adjusted: Range narrowed to $6.30–$6.50 (Midpoint $6.40).
• Occupancy: Projected to be 86.2%–87.8% by year-end (reduced from prior guidance).
• Same Property NOI: Expected to decline 10.5%–8.5% (reduced from prior guidance).
• Rental Rate Changes: Renewed/re-leased space expected to see declines of 9.0%–1.0% (straight-line).
• Dispositions: Targeting $2.10–$3.70 billion in sales of partial interests and assets.
• Construction Spending: Midpoint guidance of $1.75 billion.

Management Commentary & Risks

• Market Headwinds: The life science sector faces a "biotech bear market," reduced venture capital, and elevated new supply in key markets (Boston, San Diego, SF Bay Area), leading to lower rental rates and higher concessions.
• Capital Strategy: The company is reducing construction spending and evaluating the business strategy for 1.6 million RSF of projects to reduce funding needs. It relies on asset dispositions to fund debt reduction and construction.
• Legal Proceedings: A securities class action and derivative suits were filed in 2026 alleging misrepresentations regarding business performance and impairments. The company intends to defend vigorously.
• Debt Management: Successfully executed tender offers to reduce debt principal by $1.33 billion, though net debt reduction targets depend on future asset sales.

Investor Verification Checklist

• Debt Gain Sustainability: Verify that the $366.4 million gain on debt extinguishment is a one-time event and does not reflect core operating performance.
• Occupancy Recovery: Monitor the re-leasing of 657,492 RSF of key lease expirations that became vacant in Q1 2026 and the 1.1 million RSF of leased but undelivered space.
• Disposition Execution: Assess the ability to achieve the $2.9 billion midpoint disposition target in a market characterized by lower valuations and higher capitalization rates.
• Construction Pipeline: Review the status of the 1.6 million RSF of projects under "business and financial strategy evaluation" to determine if they will be paused, sold, or repositioned.
• Legal Exposure: Track the progress of the securities class action and the litigation regarding the New York City Option Parcel development.